07.20.18
Headquarters: Summit, NJ
twitter.com/celgene
www.celgene.com
Headcount: 7,000
Year Established: 1986
Revenues: $13,003 (+16%)
Net Income: $2,940 (+47%)
R&D: $5,915 (+32%)
TOP SELLING DRUGS
Celgene had another extremely successful year in 2017, bringing in $13 billion in total revenue, a 16% year-over-year jump. Despite that growth, a pending New Drug Application for Ozanimod shocked many when the filing was recently rejected by the FDA, and a significant pipeline asset, GED-0301 for Crohn’s disease, suffered an unexpected failure in a pivotal trial. Still, the company’s commercial portfolio grew with the approval of IDHIFA, a first-in-class targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) and an IDH2 mutation. Additionally, over the course of the year 160 were underway for about 60 different indications, and 25 new molecules entered preclinical or Phase I development.
Celegene also had an eventful year within acquisitions. Most notably, in early 2018, a transaction was closed to acquire Juno Therapeutics. Around the same time, Celgene also acquired Impact Biomedicines for an upfront payment of approximately $1.1 billion, and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. This acquisition came with the selective JAK2 inhibitor, fedratinibm, which provides the company with a late-stage treatment for myelo brosis with combination potential with other pipeline assets.
Within collaboration news, a drug discovery and development partnership with Evotec aims to identify new therapeutics in oncology. Evotec will receive an upfront payment of $65 million and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed program. Meanwhile, Abide Therapeutics also partnered with Celgene, granting the company an exclusive worldwide license for ABX-1772, a preclinical drug candidate discovered by Abide. Notably, Celgene partnered with bluebird bio to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the U.S. From that collaboration, bb2121 was granted Breakthrough Therapy Designation by the FDA based on preliminary clinical data from the ongoing Phase I study CRB-401.
In R&D, February 2018 brought positive results from the Phase III study of Pomalyst/Imnovid for the treatment of relapsed or refractory multiple myeloma. The international clinical trial is the only Phase III trial to investigate a triplet combination in patients who have all received prior lenalidomide (Revlimid), a population for which there is a growing unmet medical need.
twitter.com/celgene
www.celgene.com
Headcount: 7,000
Year Established: 1986
Revenues: $13,003 (+16%)
Net Income: $2,940 (+47%)
R&D: $5,915 (+32%)
TOP SELLING DRUGS
Drug | Indication | 2017 Sales | (+/-%) |
Revlimid | multiple myeloma, mantle cell lymphoma | $8,187 | 17% |
Pomalyst | multiple myeloma | $1,614 | 23% |
Otezla | psoriasis | $1,279 | 26% |
Abraxane | breast, lung, pancreatic cancer | $992 | 2% |
Vidaza | myelodysplastic syndrome | $628 | 3% |
Celgene had another extremely successful year in 2017, bringing in $13 billion in total revenue, a 16% year-over-year jump. Despite that growth, a pending New Drug Application for Ozanimod shocked many when the filing was recently rejected by the FDA, and a significant pipeline asset, GED-0301 for Crohn’s disease, suffered an unexpected failure in a pivotal trial. Still, the company’s commercial portfolio grew with the approval of IDHIFA, a first-in-class targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) and an IDH2 mutation. Additionally, over the course of the year 160 were underway for about 60 different indications, and 25 new molecules entered preclinical or Phase I development.
Celegene also had an eventful year within acquisitions. Most notably, in early 2018, a transaction was closed to acquire Juno Therapeutics. Around the same time, Celgene also acquired Impact Biomedicines for an upfront payment of approximately $1.1 billion, and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. This acquisition came with the selective JAK2 inhibitor, fedratinibm, which provides the company with a late-stage treatment for myelo brosis with combination potential with other pipeline assets.
Within collaboration news, a drug discovery and development partnership with Evotec aims to identify new therapeutics in oncology. Evotec will receive an upfront payment of $65 million and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed program. Meanwhile, Abide Therapeutics also partnered with Celgene, granting the company an exclusive worldwide license for ABX-1772, a preclinical drug candidate discovered by Abide. Notably, Celgene partnered with bluebird bio to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the U.S. From that collaboration, bb2121 was granted Breakthrough Therapy Designation by the FDA based on preliminary clinical data from the ongoing Phase I study CRB-401.
In R&D, February 2018 brought positive results from the Phase III study of Pomalyst/Imnovid for the treatment of relapsed or refractory multiple myeloma. The international clinical trial is the only Phase III trial to investigate a triplet combination in patients who have all received prior lenalidomide (Revlimid), a population for which there is a growing unmet medical need.